



Avexa Limited
ABN 53 108 150 750
576 Swan Street Richmond
Victoria Australia 3121

Telephone 61 3 9208 4300
Facsimile 61 3 9208 4004
Website www.avexa.com.au

ASX Release

9 August 2007

AVX AUDIO BROADCAST

AVEXA LIMITED (AVX) provides the opportunity to listen to an audio broadcast with **Dr Julian Chick, CEO and Boardroomradio** in a presentation titled "**2007 Full Year Results**".

To listen, simply click on the link below:

<http://www.brr.com.au/event/AVX/1243/26884/wmp/0r3n8iu1yw>

The presentation details are as follows:

- **2007 Full Year Results**
- **Presented by Dr Julian Chick, CEO**
- **Thursday 9 August 2007, 2.00pm AEST**

Boardroomradio offers many free services, such as:

- [Boardroomradio Alerts](#)
- Easy access to archived presentations on demand
- Podcast subscription with daily updates

Visit <http://www.brr.com.au> for more

Access archived presentations on demand by visiting www.brr.com.au

Boardroomradio also offers a free Podcast subscription, check the website for details.

For more information:

Dr. Julian Chick
Chief Executive Officer
+61 3 9208 4300

Mr Rod North
Bourse Communications
+ 61 (03) 9510-8309

www.avexa.com.au

Avexa Limited is a Melbourne-based biotechnology company with a focus on research and development of drugs for the treatment of infectious diseases, in particular diseases which have a significant unmet medical need. Avexa has dedicated resources and funding for key projects including antiviral drugs targeted against HIV Integrase and an antibiotic alternative for antibiotic-resistant bacterial infections. The Company's lead program is apricitabine (ATC) which has recently successfully completed the 21 day dosing of its Phase IIb trial. The Company continues to progress ATC towards Phase III trials. Avexa has entered into a collaboration with TargetDrug in China to identify new CCR5 inhibitors for the treatment of HIV infections.